What is the current production capacity and market role of dipyrone in China's pharmaceutical industry?

What is the current production capacity and market role of dipyrone in China's pharmaceutical industry?
Dipyrone production in China persists, albeit under strict regulatory oversight. During the COVID-19 wave in December 2022, Kaifeng city distributed 1 million dipyrone tablets alongside 200,000 ibuprofen tablets as part of health packages, sourced from local manufacturers like Kaifeng Pharmaceutical Group. At that time, the company's daily dipyrone output reached 1 million tablets, while ibuprofen production hit 2 million tablets daily. This indicates that despite the 2020 ban on certain formulations and the 2021 revocation of tablet registrations, some production lines remain active, likely for veterinary use or export to countries where dipyrone is still legal. The drug's low cost and rapid antipyretic effect make it a strategic reserve for public health emergencies, especially in resource-limited settings. However, the overall trend is declining, with manufacturers shifting focus to safer alternatives.